





Study of Maximized Skin Sensitization for the Test Item

SMART PRINT BIO VITALITY

Report

REFERENCE METHOD: ISO 10993-10:2021

STUDY DIRECTOR: Andrea da Costa

DATE OF COMPLETION OF THE

STUDY:

November 11th, 2024

MEDLAB PRODUTOS DIAGNÓSTICOS LTDA.

CONTRACT LABORATORY: Octávio Teixeira Mendes Sobrinho Street, 35

Vila Santa Catarina - Zip Code: 04376-070

São Paulo, SP - Brazil

Study code: **BSDM2**

IDENTIFICATION:

SPONSOR:

Study Number: 12916-1/2024.0

MMTECH PROJETOS TECNOLOGICOS

IMPORTACAO E EXPORTACAO LTDA

Rua Doutor Procopio Toleto Malta, 62

Zip Code: 13562-291 – São Carlos - SP – BRAZIL.



GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

Study title: Study of Maximized Skin Sensitization for the Test Item SMART PRINT

BIO VITALITY

Study number: 12916-1/2024.0

This study was conducted under my responsibility in accordance with NIT-DICLA-035 (INMETRO, Oct/19, Rev. 04) and its complementary documents, which meets the principles of Good Laboratory Practice as published by the OECD (N° 1 [ENV/MC/CHEM (98) 17]).

This study was conducted in accordance with the study plan, approved by the Sponsor and Test Facility Manager and to the standard operating procedures. This report represents a true and accurate record of the results obtained. There were no major known circumstances that may have affected the quality or integrity of the study.

All original raw data, including electronic records, documentation, signed study plan, possible additions to the study plan, final report and test item rate will be retained in the GLP files of Medlab Produtos Diagnósticos Ltda.

> **Study Director** Medlab Produtos Diagnósticos Ltda



STATEMENT OF QUALITY ASSURANCE

Study title: Study of Maximized Skin Sensitization for the Test Item SMART PRINT

BIO VITALITY

Study number: 12916-1/2024.0

Based on the Quality Assurance review, this final report was considered an accurate and true record of the data generated during the study.

This final report has been inspected for the respective study plan, standard operating procedure and raw data. Study procedures were monitored through process inspection.

The inspections were conducted in accordance with the standard operating procedures of the Quality Assurance of Medlab Produtos Diagnósticos Ltda.

Inspection dates and respective reporting dates to the Study Director and Test Facility Manager are presented below. These inspection reports are kept in the GLP files of Medlab Produtos Diagnósticos Ltda.

| Inquestion | Data of Inspection | Reporting dates | |
|---------------------|-------------------------------|-----------------|-----------------------|
| Inspection | Inspection Date of Inspection | | Test Facility Manager |
| Study plan | 08/30/2024 | 08/30/2024 | 08/30/2024 |
| Experimental phase* | 06/17 and 06/21/2024 | 07/05/2024 | 07/05/2024 |
| Raw data | 11/11/2024 | 11/11/2024 | 11/11/2024 |
| Final Report | 11/11/2024 | 11/11/2024 | 11/11/2024 |

^{*} Process inspection performed at least every 12 months

Quality Assurance Medlab Produtos Diagnósticos Ltda

Study number: 12916-1/2024.0 – English version Page 3 of 23



GENERAL INFORMATION

Contributors

Andrea da Costa Study Director

Roberta dos Santos Machado Test Facility Manager

Emine Oshiro Sakaue Quality Assurance

Suellen Karoline Moreira Bezerra Technical Support

Paloma Oliveira Technical Support

Mariucha Soares Technical Support

Victoria Ferreira Cravo Technical Support

Study dates

Study start date: September 12th, 2024

Experimental phase start: September 20th, 2024

Experimental phase end: October 18th, 2024

Study completion date: November 11th, 2024

English version: November 11th, 2024

Performing laboratory

This study was conducted at Medlab Produtos Diagnósticos Ltda, located at Rua Octávio Teixeira Mendes Sobrinho, 35 – CEP:04376-070, São Paulo – SP, Brazil.

Study plan adherence

No deviations from the study plan were recorded.

<u>Amendment 01:</u> In item 11.1 of the Study Plan, information about the steps of days 5-7 was not included: "approximately 24 hours before induction by topical application, if there is no dermal irritation, the tested area (after being properly shaved) should be exposed to 0.5 mL of Sodium Lauryl Sulfate 10% to create local irritation. The remaining SDS will be removed before the 2nd induction". There is no impact on the study, since the experimental steps were followed according to the methodology and reference related to the Study.



Archives

All raw data and original study records are the property of the Sponsor. The data will be correctly registered, signed and kept at Medlab Produtos Diagnostics Ltda for five years. Upon completion of all studies, unused/damaged test items will be retained until the expiration date and then will be discarded.



INDEX

| COOD | I A DOD A TODAY DD A CTUCE COMPLIANCE CTATEMENT | PAGE |
|-------|--|------|
| | LABORATORY PRACTICE COMPLIANCE STATEMENT | |
| | MENT OF QUALITY ASSURANCE | |
| | AL INFORMATION | |
| | SSTRACT | |
| | TRODUCTION | |
| 2.1. | Study objective | |
| 2.2. | Reference | |
| 2.3. | Weight of evidence analysis | |
| 2.4. | Animal welfare | 9 |
| 3. MA | ATERIAL AND METHOD | |
| 3.1. | Test item** | 10 |
| 3.2. | Test system | 11 |
| 3.3. | Environmental conditions | 12 |
| 3.4. | Method of administration and reason for choice | 12 |
| 3.5. | Reference item (control) | 13 |
| 3.6. | Material, reagents and equipment | 13 |
| 3.7. | Test item preparation | 14 |
| 3.8. | Experimental design | 15 |
| 3.9. | Results evaluation / Acceptance criterion | 16 |
| 4. RE | SULTS | 17 |
| 4.1. | Body weight | 17 |
| 4.2. | Challenge evaluation | 17 |
| 5. CO | ONCLUSION | 17 |
| 6. RE | FERENCES | 17 |
| | 1: Individual body weight of the test system – polar extract | |
| | 2: Individual body weight of the test system – non-polar extract | |
| TABLE | 3: challenge evaluation – polar extract | 20 |
| | 4: challenge evaluation – non-polar extract | |
| | 5: Incidence of positive reactions during challenge evaluation – polar extract | |
| | 6: Incidence of positive reactions during challenge evaluation – non-polar extra | |
| APPEN | | 23 |



| RECOGNITION CERTIFICATE OF COMPLIANCE WITH THE PRINCIPLES OF GOO |)D |
|--|----|
| LABORATORY PRACTICES | 23 |

Study number: 12916-1/2024.0 – English version

Page 7 of 23



1. ABSTRACT

The aim of this study was to evaluate the possible sensitizing effects of the test item **SMART PRINT BIO VITALITY** provided by MMTECH PROJETOS TECNOLOGICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. Skin sensitization is an immunologically mediated skin reaction to a substance, characterized in laboratory animals by the appearance of edema and erythema. The methodology used was ISO 10993-10 (2021).

For each extraction (polar and non-polar), ten guinea pigs (Cavia porcellus) had an immunological response induced through the intradermal injection of the test item in the scapula region, potentiated with the use of an adjuvant, followed by the topical application of the test item over the same location after a week apart. After the 14-day rest period, the animals were challenged with the topical application of the test item in the flank region. The control group of five animals was treated with vehicle during the induction period, and treated with the test item in the challenge period. The animals were weighed at the beginning and at the end of the experimental period, and clinically evaluated throughout the experimental period. No erythema and edema reactions were observed in the challenge assessment. According to the methodology adopted for the study, the test item SMART PRINT BIO VITALITY was considered non-sensitizing.

ICARE
Laboratório de Análises

2. INTRODUCTION

2.1. Study objective

Skin sensitization is an immunologically mediated skin reaction to a substance, characterized

in laboratory animals by the appearance of edema and erythema. The maximized method uses

an adjuvant capable of stimulating the immune response, to enhance the sensitivity of the

method. The present study aimed to evaluate the possible sensitizing effects of the test item

SMART PRINT BIO VITALITY.

2.2. Reference

The study was conducted according to ISO 10993-10: Tests for skin sensitization, 2021.

2.3. Weight of evidence analysis

For reasons related to animal welfare, prior to conducting the study, an analysis of the evidence

was performed, with available and relevant data from the test item. The testing strategy includes

an assessment of human and/or animal data related to toxic effects. Test substance known to

cause pain and discomfort due to corrosive or severely irritating properties need not be tested.

2.4. Animal welfare

Animals are maintained in the testing facility in accordance with local and international

requirements outlined in the Standard Operating Procedures. Animals with ongoing signs of

severe discomfort and/or pain at any stage of the study are humanely euthanized and the test

item properly evaluated. Animal care procedures and decision criteria for euthanasia of

moribund and severely distressed animals are described in detail in the Standard Operating

Procedures.

Study number: 12916-1/2024.0 - English version

Page 9 of 23



3. MATERIAL AND METHOD

3.1. Test item**

Identification: SMART PRINT BIO VITALITY

Receiving date at Medlab: August 6th, 2024

Category: Medical device

Batch: PVA3 004/24

Manufacturing date: April, 2024

Expiry date: April, 2026

Active ingredient(s): Not applied

CAS number of active ingredient(s): Not applied

Amorphous Silica < 5%; Silanized Silica > 50%;

Declared composition: Dispersant <4%; Photoinitiator<4%; Methacrylic

Monomers >40%; Pigments <0.07%

Physical state: Solid

Other information: Dimensions: 50x50x1,2 mm | Weight: 5g

Provided by: MMTECH PROJETOS TECNOLOGICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA.

Study number: 12916-1/2024.0 – English version Page 10 of 23

^{**}Information regarding the test item and/or reference item is the responsibility of the Sponsor.



3.2. Test system

| Species: | Cavia porcellus (Guinea pigs) |
|------------------------------------|---|
| Strain: | Dunkin-Hartley |
| Source: | Anilab, Paulínia-SP |
| Justification for the test system: | Guinea pigs are a species widely used in skin sensitization studies, and recommended in the test method |
| Number and sex: | 15 females per extraction, 5 animals in the control group and 10 animals in the test group |
| Body weight: | Healthy young adults with body weight between $300 \text{ and } 500 \text{ g}$ |
| Date of birth: | August 11 th , 2024 |
| Receiving date: | September 19 th , 2024 |
| Acclimatization: | The animals were acclimated to laboratory conditions for 5 days before starting the test; animals with any signs of abnormality were not used in the study |
| Accommodation: | The animals were kept in conventional cages for the species during the acclimation and testing period, 5 animals per cage |
| Identification: | The test system was individually identified by marking with a felt-tip pen on the flank; the boxes were identified by labels containing the study number, lot of animals and dates of the experimental phase. |

Study number: 12916-1/2024.0 – English version Page 11 of 23



Feeding:

Water:

Commercial feed for the species (Qualy Nutrição Animal – Guinea pigs, batch 234-2, manufacture: 08/21/2024, validity: 12/19/2024) supplied ad libitum during was acclimatization period; the feed is analyzed at batch to verify the presence each microbiological contaminants. The feed provided did not show contamination that could affect the purpose or integrity of the study.

Filtered water was provided *ad libitum* in the acclimatization periods; the water is periodically analyzed for the presence of chemical and microbiological contaminants. The filtered water provided did not show contamination that could affect the purpose or integrity of the study.

3.3. Environmental conditions

The environmental conditions of the test room were monitored and recorded during the experimental period. The average temperature was 21.56°C, and the average relative humidity was 66.79%. The animals were kept under automatic control of the 12/12 hours photoperiod.

3.4. Method of administration and reason for choice

The sample was applied intradermally (1st induction) and later topically in the dermis (2nd induction and challenge) of the test system as described in the methodology.



3.5. Reference item (control)

The vehicles used for the test item extraction were 0.9% sodium chloride solution (polar vehicle) and cottonseed oil (non-polar vehicle).

The quality assurance control of this assay is provided for in the reliability test carried out periodically (Periodic Positive Control). The last evaluation was carried out in September/2024, using 15 animals (5 animals in the control group and 10 animals in the test group), and the substance α -hexylcinnamaldehyde described in the table below was considered sensitizing (positive reactions grades 1 and 2 in test group animals).

Positive control: α – Hexylcinnamaldehyde

CAS number: 101-86-0

Batch: A4 30376-QA4

Manufacturing date: 09/08/2022

Expiry date: 06/07/2025

3.6. Material, reagents and equipment

<u>Materials</u>: Bottle with lid, gauze, syringe, sterile needle, felt-tip pen, hypoallergenic tape/adhesive tape, micropore, scissors, filter paper, cotton, cotton swab.

<u>Reagents:</u> 0.9% sodium chloride solution, cottonseed oil, 10% sodium dodecyl sulfate (SDS), liquid vaseline and complete Freund's adjuvant (FCA).

Equipment: Electronic scale, trimmer machines and incubator.



3.7. Test item preparation

Extraction of the test item was performed in accordance with ISO 10993-12 (2021). The test item was extracted at 50°C for 72 hours in an incubator in two vehicles (polar and non-polar) in a ratio of 3 cm² of test item to 1 mL of vehicle. The extracts were used within 24 hours of preparation.

Polar extraction:

Total prepared for 1st induction: 50 cm² of test item for 16,7 mL of 0.9% sodium chloride solution.

Total prepared for 2nd induction: 50 cm² of test item for 16,7 mL of 0.9% sodium chloride solution.

Total prepared for challenge: 50cm^2 of test item for 16,7 mL of 0.9% sodium chloride solution. The liquid resulting from this process (extract) presented a homogeneous and colorless appearance, as per the original color of the vehicle, without the presence of particulates, and was not submitted to any other additional process.

Non-polar extraction:

Total prepared for 1st induction: 50 cm² of test item for 16,7 mL of cottonseed oil.

Total prepared for 2nd induction: 50cm² of test item for 16,7 mL of cottonseed oil.

Total prepared for challenge: 50 cm² of test item for 16,7 mL of cottonseed oil.

The liquid resulting from this process (extract) presented a homogeneous and yellow appearance, according to the original color of the vehicle, without the presence of particulates, and was not submitted to any other additional process.



3.8. Experimental design

The test system was weighed before the beginning and at the end of the experiment. Trichotomy was performed approximately 24 hours before each application.

At the first induction (day 0), each animal received three pairs of intradermal injections (0.1 mL each injection) in the scapula region, with one injection of each pair being applied on each side of the midline, in a mirror fashion. The contents of the test group injections are described below:

- Injection 1: mixture 1:1(v/v) of FCA + 0.9% sodium chloride solution or cottonseed oil.
- Injection 2: undiluted test item extract.
- Injection 3: extract of the test item undiluted in a 1:1 ratio with the solution from injection 1 The control group received three pairs of intradermal injections of 0.1 mL each, applied in the same sites as the animals in the test group, as described below:
- Injection 1: mixture 1:1 v/v of FCA + 0.9% sodium chloride solution or cottonseed oil.
- Injection 2: 0.9% sodium chloride solution or undiluted cottonseed oil.
- Injection 3: 0.9% sodium chloride solution or cottonseed oil in a 1:1 ratio with injection solution 1.

On day 6, the animals had the scapula area pretreated with 10% SDS massaged into the skin. On day 7, the animals received applications of filter paper soaked in 0.5 mL (0.25 mL on each side) of the test item extract (experimental group) and 0.5 mL (0.25 mL on each side) of cottonseed oil (control group) in the scapula region. The occlusive dressings remained in contact with the animals' skin for 48 hours, and after removal, the area was cleaned with a 0.9% sodium chloride solution.

On the 21st, the challenge period began. Animals (control and experimental groups) received cotton dressings soaked in 0.5 mL of undiluted test item extract. The occlusive dressing was kept in contact with the skin for 24 hours, and after removal, the area was cleaned with a 0.9% sodium chloride solution. Approximately 24 and 48 hours after dressing removal (48 and 72 hours after challenge exposure), skin reactions (erythema and edema) were assessed. Assessments were made according to the Magnusson and Kligman grading scale.



3.9. Results evaluation / Acceptance criterion

The criteria established for classifying the sample as a potential sensitizing agent were:

- a) Within 48 and/or 72 hours, 30% or more of the animals tested had a positive response (grade ≥ 1), in the absence of similar results in the control group.
- b) A positive reaction presented within 48 hours persistent at 72 hours in at least one animal, in the absence of similar results in the control group.



4. RESULTS

4.1. Body weight

Tables 1 and 2 show the initial and final body weight of the test systems, as well as the body weight variation. All animals showed weight gain at the end of the experimental period.

4.2. Challenge evaluation

Tables 3 and 4 show the evaluation of dermal reactions after challenge. Tables 5 and 6 show the incidence of positive reactions. Erythema and edema reactions were not observed for both polar and non-polar extracts.

5. CONCLUSION

According to the methodology adopted for the study, the test item **SMART PRINT BIO VITALITY** was considered non-sensitizing.

6. REFERENCES

INMETRO: NIT-DICLA-035 - Principles of Good Laboratory Practice – GLP, Rev. 04, October/2019 and its complementary documents.

ISO 10993:10 – Biological evaluation of medical devices. Part 10: Tests for skin sensitization, 2021.

ISO 10993:12 – Biological evaluation of medical devices. Part 12: Sample Preparation and Reference Materials, 2021.

OECD Environmental Health and Safety Publications, Series on Principles of Good Laboratory Practice and Compliance Monitoring. No. 1.,41p., Paris, 1998 (17).



TABLE 1: Individual body weight of the test system – polar extract

| Test | Body weight (g) | | |
|---------|-----------------|---------------|-----------|
| group | Initial | Final | Variation |
| 01 | 310 | 468 | 158 |
| 02 | 308 | 412 | 104 |
| 03 | 346 | 428 | 82 |
| 04 | 300 | 396 | 96 |
| 05 | 300 | 398 | 98 |
| 06 | 352 | 446 | 94 |
| 07 | 302 | 388 | 86 |
| 08 | 346 | 410 | 64 |
| 09 | 316 | 424 | 108 |
| 10 | 314 | 428 | 114 |
| Control | В | ody weight (g | g) |
| group | Initial | Final | Variation |
| 01 | 342 | 482 | 140 |
| 02 | 328 | 420 | 92 |
| 03 | 300 | 390 | 90 |
| 04 | 346 | 426 | 80 |
| 05 | 322 | 404 | 82 |



TABLE 2: Individual body weight of the test system – non-polar extract

| T4 | I | Body weight (g | g) |
|---------------|--------------------|----------------|-----------|
| Test group | Initial | Final | Variation |
| 01 | 322 | 416 | 94 |
| 02 | 304 | 378 | 74 |
| 03 | 322 | 402 | 80 |
| 04 | 322 | 414 | 92 |
| 05 | 318 | 386 | 68 |
| 06 | 324 | 428 | 104 |
| 07 | 332 | 432 | 100 |
| 08 | 316 | 466 | 150 |
| 09 | 302 | 400 | 98 |
| 10 | 300 | 408 | 108 |
| Control group | Body weight (g)138 | | |
| Control group | Initial | Final | Variation |
| 01 | 300 | 402 | 102 |
| 02 | 316 | 420 | 104 |
| 03 | 300 | 404 | 104 |
| 04 | 344 | 418 | 74 |
| 05 | 318 | 400 | 82 |



TABLE 3: Challenge evaluation – polar extract

| Took ones | Challenge evaluation | |
|---------------|----------------------|----------|
| Test group | 48 hours | 72 hours |
| 01 | 0 | 0 |
| 02 | 0 | 0 |
| 03 | 0 | 0 |
| 04 | 0 | 0 |
| 05 | 0 | 0 |
| 06 | 0 | 0 |
| 07 | 0 | 0 |
| 08 | 0 | 0 |
| 09 | 0 | 0 |
| 10 | 0 | 0 |
| Control group | Challenge evaluation | |
| Control group | 48 hours | 72 hours |
| 01 | 0 | 0 |
| 02 | 0 | 0 |
| 03 | 0 | 0 |
| 04 | 0 | 0 |
| 05 | 0 | 0 |

| 0 | No visible alteration |
|---|---------------------------------|
| 1 | Discrete or Irregular Erythema |
| 2 | Moderate and Confluent Erythema |
| 3 | Intense Erythema and/or Edema |

Magnusson and Kligman Scale (reactions ≥ 1 are considered positive)



TABLE 4: Challenge evaluation – non-polar extract

| Test | Challenge evaluation | | |
|---------|----------------------|------------|--|
| group | 48 hours | 72 hours | |
| 01 | 0 | 0 | |
| 02 | 0 | 0 | |
| 03 | 0 | 0 | |
| 04 | 0 | 0 | |
| 05 | 0 | 0 | |
| 06 | 0 | 0 | |
| 07 | 0 | 0 | |
| 08 | 0 | 0 | |
| 09 | 0 | 0 | |
| 10 | 0 | 0 | |
| Control | Challenge | evaluation | |
| group | 48 hours | 72 hours | |
| 01 | 0 | 0 | |
| 02 | 0 | 0 | |
| 03 | 0 | 0 | |
| 04 | 0 | 0 | |
| 05 | 0 | 0 | |

| 0 | No visible alteration |
|---|---------------------------------|
| 1 | Discrete or Irregular Erythema |
| 2 | Moderate and Confluent Erythema |
| 3 | Intense Erythema and/or Edema |

Magnusson and Kligman Scale (reactions ≥ 1 are considered positive)



TABLE 5: Incidence of positive reactions during challenge evaluation – polar extract

| Groups | 48 hours | 72 hours |
|--------------|-----------|-----------|
| Experimental | 0/10 = 0% | 0/10 = 0% |
| Control | 0/5 = 0% | 0/5 = 0% |

TABLE 6: Incidence of positive reactions during challenge evaluation – non-polar extract

| Groups | 48 hours | 72 hours |
|--------------|-----------|-----------|
| Experimental | 0/10 = 0% | 0/10 = 0% |
| Control | 0/5 = 0% | 0/5 = 0% |



APPENDIX 1

RECOGNITION CERTIFICATE OF COMPLIANCE WITH THE PRINCIPLES OF GOOD LABORATORY PRACTICES

National Institute of Metrology, Quality and Technology – Inmetro General Coordination for Accreditation



Statement of GLP Compliance

GLP Recognition No. GLP BPL 0041

Initial Recognition: March 06th, 2014

Medlab Produtos Diagnósticos Ltda.

Rua Octavio Teixeira Mendes Sobrinho, 35 - Vila Santa Catarina - São Paulo - SP - Brasil

General Coordination for Accreditation of Inmetro grants to the above mentioned test facility the recognition of compliance with the OECD Principles of Good Laboratory Practice as part of the Brazilian GLP Monitoring Program to carry out non-clinical health and environmental safety studies, as described in the scope below:

| Areas of expertise | Categories of Test Items |
|--|---|
| Toxicity Studies, Efficacy Studies; Citotoxicity Studies | Pesticides, Their Components and Suchlike; Pharmaceutical Products; Veterinary Drugs; Sanitizers; Industrial Chemicals; Health Products; Medical Devices; Cosmetics; Food Additives |

Note: Categories of test items "pesticides", "pharmaceutical products", "cosmetics", "wood preservative", "feed additives", "veterinary drugs", "sanitizers", "industrial chemicals", "nemedial for treatments of effluents and natural ecosystems" and "medical devices" are covered by Brazil's full adherence to the OECD Council Acts related to the Mutual Acceptance of Data (MAD) on Good Laboratory Practice.

MARCOS VALERIO Assinado de forma digital por MARCOS VALERIO BARRADAS:66801095749
Dados: 2023.11.08 14:47:36 -03'00'

MARCOS VALERIO BARRADAS General Coordinator for Accreditation Substitute

The current status of recognition must be checked on the email address http://www.inmetro.gov.br/monitoramento_BPL/certificados

MOD-CGCRE-027 - Rev. 09 - Apr. OUT/23 - Pg. 2/03

Study number: 12916-1/2024.0 – English version

Page 23 of 23